Previous close | 24.09 |
Open | 24.23 |
Bid | 23.20 |
Ask | 25.40 |
Strike | 50.00 |
Expiry date | 2024-06-21 |
Day's range | 24.08 - 24.23 |
Contract range | N/A |
Volume | |
Open interest | 523 |
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.